The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a significant substantia